The Globe and Mail reports in its Thursday edition that President Donald Trump is threatening large tariffs on generic drugs that are not made in the United States, potentially complicating recent efforts by Canada's government to boost domestic production of pharmaceuticals. The Globe's Chris Hannay writes that Mr. Trump posted on social media Tuesday that his administration would impose 100-per-cent tariffs on generic pharmaceuticals starting on Aug. 1, 2028, a figure that would rise to 200 per cent a year later. "This is done in order to RESHORE Generic Pharmaceutical Production into America, with a penalty to those Companies that decide not to build Plant and Equipment within the stated period of time given to them," Mr. Trump's post said. It is the latest in a series of measures that the Trump administration has taken to try to boost domestic drug production. In June, the administration announced that seven drug companies would participate in a pilot to get speedier regulatory review for new manufacturing facilities. Of the Canadian-made drugs exported to the U.S., 79 per cent were generics. Shares of Apotex Health were down 8 per cent Wednesday. About 89 per cent of U.S. prescriptions are filled with generics.